PTC Therapeutics, Inc. Forecast, price target & analysts
PTC Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
PTC Therapeutics, Inc. Classifications & Recommendation
PTC Therapeutics, Inc. Price Target
| Target Price | $106.08 |
| Price | $62.28 |
| Potential |
70.33%
register free of charge
|
| Number of Estimates | 16 |
|
16 Analysts have issued a price target PTC Therapeutics, Inc. 2027 .
The average PTC Therapeutics, Inc. target price is $106.08.
This is
70.33%
register free of charge
$136.50
119.17%
register free of charge
$70.70
13.52%
register free of charge
|
|
| A rating was issued by 21 analysts: 17 Analysts recommend PTC Therapeutics, Inc. to buy, 3 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the PTC Therapeutics, Inc. stock has an average upside potential 2027 of
70.33%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 1.73 | 1.29 |
| 1,090.11% | 25.64% | |
| EBITDA Margin | 50.97% | 30.30% |
| 29.53% | 40.55% | |
| Net Margin | 39.44% | 12.02% |
| 195.51% | 69.53% |
16 Analysts have issued a sales forecast PTC Therapeutics, Inc. 2026 . The average PTC Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an PTC Therapeutics, Inc. EBITDA forecast 2026. The average PTC Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 PTC Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average PTC Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 7.72 | 1.86 |
| 8.53% | 75.91% | |
| P/E | 33.54 | |
| EV/Sales | 4.57 |
16 Analysts have issued a PTC Therapeutics, Inc. forecast for earnings per share. The average PTC Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
PTC Therapeutics, Inc....
Current PTC Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Sep 22 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Jul 31 2026 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | Jul 20 2026 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Jul 16 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Sep 22 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Jul 31 2026 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Jul 20 2026 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Jul 16 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
